Comparison of Fludarabine/Treosulfan Conditioning with Melphalan-Based Sequential Conditioning in Patients with MDS and Increased Blasts Undergoing Upfront Transplantation
Authors:
- Judith MetzdorfJudith Metzdorf
- Artur SchneiderArtur Schneider
- Jacob PykaJacob Pyka
- Annemarie MohringAnnemarie Mohring
- Jennifer KaiversJennifer Kaivers
- Tim LohmannTim Lohmann
- Hans Christian ReinhardtHans Christian Reinhardt
- Nicolaus KrögerNicolaus Kröger
- Christina RautenbergChristina Rautenberg
- Thomas SchroederThomas Schroeder
Open Access
Abstract
Background: Upfront allogeneic stem cell transplantation (allo-SCT) without pretransplant cytoreduction is an established concept in patients with myelodysplastic syndromes with increased blasts (MDS-IB), but the optimal conditioning strategy remains to be defined. While fludarabine and treosulfan (Flu/Treo) has become an established regimen for older patients based on its favorable ratio between toxicity and efficacy, its impact when used in the context of upfront transplant is less well described. Methods: Here, we retrospectively investigated Flu/Treo as the backbone for conditioning in 35 patients with MDS-IB (median blast count 13%) receiving upfront transplantation. Results: Outcomes in this high-risk cohort (75% IPSS-M high or very high) were promising, with an estimated 2-year overall (OS), relapse-free survival (RFS) and non-relapse mortality (NRM) of 76%, 56% and 13%, respectively. Relapse was the major cause of treatment failure, reflected by a relapse incidence (CIR) of 31%. We identified the TP53 mutation status as the main driver of relapse (2-year RFS TP53 mutated 17% vs. 67%, p = 0.01; 2-year CIR 54% vs. 24%, p = 0.08) and an adverse prognostic factor, while the pretransplant blast count did not affect the post-transplant outcome. Intensification with the addition of melphalan (Mel, n = 18) to a sequential conditioning approach did not improve the outcome (Mel vs. Flu/Treo 2-year OS 62% vs. 87%, RFS 50% vs. 63%, CIR 37% vs. 24%, NRM 14% vs. 12%, all not significant). Conclusions: This pilot series shows that upfront transplantation using Flu/Treo conditioning in high-risk MDS patients facilitates promising post-transplant outcomes and may serve as a backbone to further improve these results through innovative peri-transplant interventions.Keywords
This publication has 32 references indexed in Scilit:
- Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study GroupTransplantation and Cellular Therapy, 2025
- Current challenges in conditioning regimens for MDS transplantationBlood Reviews, 2024
- Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialThe Lancet Haematology, 2024
- Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMTBone Marrow Transplantation, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialAmerican Journal of Hematology, 2022
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialThe Lancet Haematology, 2020
- Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous LeukemiaTransplantation and Cellular Therapy, 2019
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromeAmerican Journal of Hematology, 2013